Výsledky vyhledávání

Akademický článek

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.

Autor: Al-Sudani H; Internal Medicine Department, Einstein Medical Center Montgomery, Philadelphia, PA, USA., Ni Y; Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA., Jones P; Magee Women's Research Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Karakilic H; Magee Women's Research Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Cui L; Trillium Therapeutics Inc, 2488 Dunwin Dr., Mississauga, ON, L5L 1J9, Canada., Johnson LDS; Trillium Therapeutics Inc, 2488 Dunwin Dr., Mississauga, ON, L5L 1J9, Canada., Rose PG; Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA., Olawaiye A; Magee Women's Research Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA.; Magee Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA.; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Edwards RP; Magee Women's Research Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA.; Magee Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA.; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, 15213, USA., Uger RA; Trillium Therapeutics Inc, 2488 Dunwin Dr., Mississauga, ON, L5L 1J9, Canada., Lin GHY; Trillium Therapeutics Inc, 2488 Dunwin Dr., Mississauga, ON, L5L 1J9, Canada., Mahdi H; Magee Women's Research Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA. mahdihs@upmc.edu.; Magee Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA. mahdihs@upmc.edu.; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, 15213, USA. mahdihs@upmc.edu.

Publikováno v: NPJ precision oncology [NPJ Precis Oncol] 2023 Jul 19; Vol. 7 (1), pp. 69. Date of Electronic Publication: 2023 Jul 19.

Zobrazit plný text záznamu

Akademický článek

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.

Autor: Kruglov O; Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, 3708 Fifth Avenue, 5th Floor, Suite 500.68, Pittsburgh, PA, 15213, USA., Johnson LDS; Trillium Therapeutics Inc, Mississauga, ON, Canada., Minic A; Department of Immunology and Microbiology, University of Colorado, Aurora, CO, USA., Jordan K; Department of Immunology and Microbiology, University of Colorado, Aurora, CO, USA., Uger RA; Trillium Therapeutics Inc, Mississauga, ON, Canada., Wong M; Trillium Therapeutics Inc, Mississauga, ON, Canada., Sievers EL; Trillium Therapeutics Inc, Mississauga, ON, Canada., Shou Y; Trillium Therapeutics Inc, Mississauga, ON, Canada., Akilov OE; Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, 3708 Fifth Avenue, 5th Floor, Suite 500.68, Pittsburgh, PA, 15213, USA. akilovoe@upmc.edu.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2022 Apr; Vol. 71 (4), pp. 919-932. Date of Electronic Publication: 2021 Sep 14.

Zobrazit plný text záznamu

Akademický článek

Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4 ⁺ BTLA ⁺ T Cells in Tumor Microenvironment of Mycosis Fungoides.

Autor: Jiang TT; Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15261, USA., Kruglov O; Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15261, USA., Lin GHY; Trillium Therapeutics Inc., Mississauga, ON L5L 1J9, Canada., Minic A; Department of Immunology and Microbiology, University of Colorado, Aurora, CO 80045, USA., Jordan K; Department of Immunology and Microbiology, University of Colorado, Aurora, CO 80045, USA., Uger RA; Trillium Therapeutics Inc., Mississauga, ON L5L 1J9, Canada., Wong M; Trillium Therapeutics Inc., Mississauga, ON L5L 1J9, Canada., Shou Y; Trillium Therapeutics Inc., Mississauga, ON L5L 1J9, Canada., Akilov OE; Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Publikováno v: Cancers [Cancers (Basel)] 2021 Nov 28; Vol. 13 (23). Date of Electronic Publication: 2021 Nov 28.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.

Autor: Querfeld C; Division of Dermatology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA. Electronic address: cquerfeld@coh.org., Thompson JA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Taylor MH; Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., DeSimone JA; Melanoma and Skin Oncology Center, Inova Health System, Fairfax, VA, USA., Zain JM; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Shustov AR; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Johns C; School of Medicine, Oregon Health and Science University, Portland, OR, USA., McCann S; Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Lin GHY; Trillium Therapeutics, Mississauga, ON, Canada., Petrova PS; Trillium Therapeutics, Mississauga, ON, Canada., Uger RA; Trillium Therapeutics, Mississauga, ON, Canada., Molloy N; Trillium Therapeutics, Mississauga, ON, Canada., Shou Y; Trillium Therapeutics, Mississauga, ON, Canada., Akilov OE; Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2021 Nov; Vol. 8 (11), pp. e808-e817. Date of Electronic Publication: 2021 Oct 07.

Zobrazit plný text záznamu

Akademický článek

Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.

Autor: Diamanti P; Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant Filton, Bristol, United Kingdom.; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Cox CV; Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant Filton, Bristol, United Kingdom., Ede BC; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom., Uger RA; Trillium Therapeutics Inc., Mississauga, ON, Canada; and., Moppett JP; Bristol Royal Hospital for Children, Bristol, United Kingdom., Blair A; Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant Filton, Bristol, United Kingdom.; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Publikováno v: Blood advances [Blood Adv] 2021 Sep 28; Vol. 5 (18), pp. 3694-3708.

Zobrazit plný text záznamu

Akademický článek

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.

Autor: Ansell SM; Division of Hematology, Mayo Clinic, Rochester, Minnesota. ansell.stephen@mayo.edu., Maris MB; Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, Colorado., Lesokhin AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Chen RW; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Flinn IW; Sarah Cannon Research Institute, Nashville, Tennessee.; Tennessee Oncology, Nashville, Tennessee., Sawas A; Center for Lymphoid Malignancies, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York., Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Villa D; Division of Medical Oncology and Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Percival MM; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Division of Hematology, University of Washington, Seattle, Washington., Advani AS; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio., Foran JM; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida., Horwitz SM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Mei MG; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Zain J; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Savage KJ; Division of Medical Oncology and Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Querfeld C; Department of Hematology and Hematopoietic Transplantation, City of Hope Medical Center, Duarte, California., Akilov OE; Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Johnson LDS; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Catalano T; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Petrova PS; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Uger RA; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Sievers EL; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Milea A; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Roberge K; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., Shou Y; Trillium Therapeutics Inc., Mississauga, Ontario, Canada., O'Connor OA; University of Virginia Cancer Center, Charlottesville, Virginia.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Apr 15; Vol. 27 (8), pp. 2190-2199. Date of Electronic Publication: 2021 Jan 15.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání